Nurix Therapeutics, Inc. Detailed Financials

Full historical quarterly statements

Metric2026-02-282025-11-302025-08-312025-05-312025-02-282024-11-302024-08-312024-05-31
Total Revenue6.3M13.6M7.9M44.1M18.5M13.3M12.6M12.1M
Cost of Goods Sold84.1M4.6M5.0M78.1M69.7M67.2M55.5M48.9M
Gross Profit-77.9M8.9M2.9M-34.0M-51.2M-53.9M-42.9M-36.8M
R&D Expenses080.9M86.1M78.1M69.7M67.2M55.5M48.9M
Operating Expenses14.6M92.0M94.3M14.3M11.7M10.7M11.7M11.7M
Operating Income-92.5M-83.1M-91.4M-48.3M-62.9M-64.7M-54.6M-48.5M
Other Income / Gains5.3M4.9M5.0M5.6M6.5M6.1M5.7M4.1M
Net Income-87.2M-78.2M-86.4M-43.5M-56.4M-58.5M-49.0M-44.5M
EPS (Diluted)-0.79-0.82-1.03-0.52-0.67-0.75-0.67-0.71
Reported CurrencyUSDUSDUSDUSDUSDUSDUSDUSD
Gross Profit Ratio-12.4580.6590.367-0.773-2.775-4.061-3.407-3.046
General And Administrative Expenses14.6M13.6M13.2M14.3M11.7M10.7M11.7M11.7M
Selling And Marketing Expenses00000000
Selling General And Administrative Expenses14.6M13.6M13.2M14.3M11.7M10.7M11.7M11.7M
Other Expenses0-2.5M-5.0M-78.1M-69.7M-67.2M-55.5M-48.9M
Cost And Expenses98.7M96.7M99.3M92.4M81.3M77.9M67.2M60.6M
Interest Income04.9M5.0M5.6M6.5M6.1M5.7M4.1M
Interest Expense00000000
Depreciation And Amortization09.3M5.0M2.2M2.4M1.2M2.4M2.3M
Ebitda-87.2M-69.0M-81.4M-40.5M-54.0M-57.3M-46.5M-42.1M
Ebitdaratio-13.943-5.079-10.314-0.918-2.926-4.313-3.692-3.484
Operating Income Ratio-14.794-6.12-11.577-1.097-3.407-4.867-4.338-4.014
Income Before Tax-87.2M-78.2M-86.4M-42.7M-56.4M-58.5M-48.9M-44.5M
Income Before Tax Ratio-13.943-5.761-10.948-0.969-3.054-4.407-3.883-3.676
Income Tax Expense000760K08K82K90K
Net Income Ratio-13.943-5.761-10.948-0.987-3.054-4.407-3.889-3.684
Epsdiluted-0.79-0.82-1.03-0.52-0.67-0.75-0.67-0.71
Weighted Average Shs Out110.1M95.1M84.2M83.9M83.6M78.4M72.8M62.4M
Weighted Average Shs Out Dil110.1M95.1M84.2M83.9M83.6M78.4M72.8M62.4M